Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ot...astro signs?.....cool.....http://news.yahoo.com/news?tmpl=index2&cid=1756
Robert Kerbal, cited in previous post....http://psa-rising.com/med/angio/folkman-nrc-112002.shtml
news....Robert D'Amato, panzem researcher, involved in discovery.....way down the page...http://www.sciencedaily.com/releases/2005/01/050126113105.htm
Yes, $5.75 might be a short term target, but I think we may have a 2003 OXGN type rally, $2 to $18 in a few weeks, just need a couple of pr's.....A side note, ENMD is acting like it did in January 2000, then ENMD peaked March 1, I'm thinking this current ramp may run til March 1, 2005.
It appears we have a cup and handle breakout with nice volume....gg
Self-reporting Nano-material for Sustained Intraocular Drug Delivery This project involves the development of a new material to overcome the largest barrier to effective treatment of eye disorders: the difficulty in delivering appropriate doses of drugs to key regions of the eye for sustained periods. A cross-disciplinary team of UCSD researchers has exploited a customized nanomaterial that enables them to deliver drugs in a sustained-release manner, and to monitor drug levels in the eye, non-invasively, throughout the course of treatment. The novelty of this approach lies in the fact that this customized nano-material has optical properties that allows one to monitor drug levels in the implant without invasive procedures to the eye. The optical properties of this material change in a reproducible fashion as the concentration of drug decreases within the implant, making this an ideal material for drug delivery and non-invasive reporting of drug levels. The use of this nanomaterial minimizes the number of injections required, reducing cost, scarring and the likelihood of infection, and ensures that the patient receives an effective dose throughout the treatment period.The research team has already obtained promising proof-of-concept data showing that: This material is non-toxic and remains within the vitreum for 3 weeks or longer;One can monitor the optical characteristics of the implants and therefore the quantity of drugs remaining by viewing them through the iris, without injury to the eye; andCertain anti-angiogenic drugs useful for local treatment of macular degeneration and diabetic retinopathy are released slowly from these particles.The researchers are seeking a commercial partner to support further research and development to bring this novel drug delivery system to the market and thereby improve patient care. The research team combines UCSD's expertise in nano-fabrication, photonic system design, bioengineering, and patient care for eye disease. The studies will be carried out in the new, state-of-the-art, Jacobs Retina Center, opened at UCSD in 2004. The Jacobs Retina Center also has dedicated clinical trial facilities that can be used to further test this drug delivery system. Recent data on this nanomaterial as a self-reporting drug delivery vehicle can be found in: Science (2003) v. 299, 2045-2047. A patent is pending.Powerpoint Presentation Download About TechTIPS / Newsletter / Search / Contact Us / Home
Researchers say they can measure new cancer drug Canadian Press Updated: Tue. Jan. 18 2005 9:43 AM ET TORONTO — An international team of researchers led by some Toronto scientists has found a way to measure the effects of a new class of cancer drugs that are believed to hold great promise. The scientists believe their finding could hold a key to the future success of this form of therapy, known as anti-angiogenesis. A spokesperson for the Canadian Cancer Society said the test, led by Dr. Bob Kerbel at Sunnybrook and Women's College Health Sciences Centre, hasn't yet been proven to work in humans and isn't likely to be available on an individual basis any time soon. "Those caveats not withstanding . . . what Bob has shown as I understand it is a very exciting proof of principle that in fact you can' monitor and you can measure anti-angiogenesis therapies and treatments using something that could be developed into a fairly simple or at least straightforward blood test," said Michael Wosnick, executive director of the cancer society's research arm, the National Cancer Institute of Canada. The cancer society helps fund Kerbel's work. "I have a lot of hope for anti-angiogenesis for a really, really important mainline treatment for all kinds of cancers," Wosnick added. Angiogenesis is the term for the development of blood vessels to feed tissues - or in the case of cancer, tumours. The idea that you could starve a tumour by turning off its blood supply - anti-angiogenesis - was first advanced in the early 1970s by Harvard-based cancer researcher Judah Folkman. It's a theory that has experienced a roller-coaster ride of reaction from the scientific community, which has ridiculed and embraced it by turn, Kerbel said in an interview Monday. Some anti-angiogenic drugs have shown great promise in mice, but the results in humans have disappointed. Kerbel said one of the main problems is there has been no way to measure the effect of the drugs, meaning its has been impossible to determine the optimal dose. With traditional cancer therapies, dosing has followed a brutal regime that involves subjecting patients to the highest dose they can tolerate, followed by recovery intervals. There is some suggestion that with anti-angiogenic drugs less might be more. But until researchers can measure how the drugs are doing, there'd be no way to effectively tell. Kerbel's team has found what scientists call a biological marker that they believe solves the conundrum. They found that measuring levels of endothelial cells and endothelial progenitor cells circulating in the blood stream can be a good indicator of whether a therapy is inhibiting angiogenesis. These types of cells are believed to originate in the bone marrow and are known to play a key role in the development of blood vessels. "We can actually say that we have a way to measure the angiogenic activity. And if we have a way to measure angiogenic activity, we have a way to measure anti-angiogenic activity," said first author Yuval Shaked, a post-doctoral fellow working with Kerbel. The findings could be an immeasurable help to drug companies previously stymied in efforts to set appropriate doses for their therapies or prove to regulators that they work. "It's huge for them," Kerbel said. "Because they are investing enormous amounts of money into these sorts of drugs. Sometimes hundreds of millions of dollars. "And at the end of the day, everything they've done has failed, not because they don't have an active drug . . . but because they weren't able to assess it properly."© Copyright 2004 Bell Globemedia Inc.
Technology that could double the effectiveness of cancer drugs studied at Yale22 Jan 2005 To identify the best treatment for recurrent ovarian cancer, researchers at Yale School of Medicine are studying a technology called the Yale apoptosis assay in combination with another technology called the ChemoFX assay, which could double the response rate to existing drugs. In patients with recurrent ovarian cancer, it is often difficult to select an effective treatment because the tumor develops resistance to many drugs. Currently, physicians select a drug and must wait about six months to see whether it is effective on a particular patient. "These two new assays will take the guesswork out of cancer treatment," said lead investigator, Gil Mor, M.D., associate professor of obstetrics and gynecology and reproductive sciences at Yale School of Medicine. "In patients with very limited time left to live, six months can feel like an eternity when they may have to start a whole new course of treatment if it proves ineffective." Mor's lab developed the Yale apoptosis assay based on a biological principle that when a drug is effective, it will induce apoptosis (cell death) in the cancer cell. If the cancer cell is resistant to a drug, apoptosis does not occur. Mor said, "The Yale apoptosis assay will determine whether a drug kills the tumor. The ChemoFX assay will determine whether a drug stops tumor growth. Used together, both assays will distinguish drugs that can stop the growth of the tumor and/or kill the tumor. This was not possible before." "This test will help physicians predict whether a patient will respond to a specific drug, much like they test bacteria for sensitivity to antibiotics," Mor added. The technology will be studied with various cancers, beginning with ovarian cancer. The clinical trial is a multi-center study for validation of the assays. Each assay will be evaluated independently and then in combination. The Yale research team partnered with Precision Therapeutics, Inc., (PTI) developers of the ChemoFX assay and is seeking patients from Yale and surrounding communities and from 10 other sites around the country. PTI exclusively licensed the Yale apoptosis assay from Yale. Recruitment for the study will be complete in June 2005, with results available about one year later. The Yale clinical trial is led by Thomas Rutherford, M.D., associate professor of gynecology at Yale School of Medicine. Karen N. Peartkaren.peart@yale.eduYale University Save time! Get the latest medical news in your email every week with our newsletter.Send your press releases to pressrelease@medicalnewstoday.com
a patient ponders AI and chemo....http://prostate-help.org/caangct.htm
thanks Aaron....hmmm....your post #1649 is interesting.....The next shoe to drop may be Winship hif news, we haven't heard from them in awhile...gg
multipost relply....I guess I got a bit carried away, but company officials may be hinting at a panzem--taxol combo trial. I thought that was an interesting PR, so did alot of others judging by the volume.
I'm surprised at the subdued response on this board to yesterdays news. Heck, I'm pumped, ENMD is rocking, I think they have the best AI, outside chance ENMD is the top perfoming stock on the entire board in 2005....Go ENMD!
from May 21, 2002 pr, phase 1 panzem with taxotere trial.... "A maximum tolerated dose of Panzem was not reached".... "Further, two responding patients have reported stable disease for over six months while taking oral Panzem alone ONCE A DAY" .....Looks like patients received a minuscule dose of Panzem, but responses were reported including one complete response.
yep, that song's like a Valium...gg.....cool!.... "raise the possibility of developing Panzem as a combo treatment with chemo"......http://biz.yahoo.com/ap/050119/entremed_cancer_drug_1.html
It's a marvelous night for a moondance, with the stars up above in your eyes....post # 1597....hey!
wow...researchers can measure AI's efficacy, enter cancer in box, scroll down after page loads....http://dailynews.yahoo.com/
just out, see post #1594 too....http://news.bbc.co.uk/2/hi/uk_news/england/cambridgeshire/4184495.stm
medical breakthroughs in 2005!... Fits with my cycle work, I hope it's AI's.....http://www.coasttocoastam.com/shows/2005/01/17.html
stem cells and angiogenesis....http://www.scripps.edu/news/press/072602.html
re: roche...oh ya....I knew that was coming...see post #1293....and #1444....and #1325......ENMD moon shot soon?
Elan's nanocrystal's in J and J phase 3 trial....http://www.rte.ie/business/2005/0112/elan.html
I keep thinking about that complete response reported in the taxotere and panzem capsule trial...Aventis (taxotere) .....http://www.elan.com/DrugDelivery/Announcements/20_01_2004.asp
I wonder if there is a connection between James Burns stem cell background and Celgenes stem cell program.
" Light selling during the handle formation leads to a greater potential for higher prices after the cup and handle formation".....http://www.trade10.com/Cuphandle.html
cup and handle.....Nice handle forming...She bounced off $3 like a golf ball on concrete.....looking good
therapeutic angiogenesis....http://www.wbir.com/news/news.aspx?storyid=22147
leaky vessels, down the page.....http://www.med.unibs.it/~airc/sandra/pathology.html
connect the "dots"...Winship...."These angionenic vessels are very porous, which allowed the quantum dots to leak and accumulate at the tumor sites"......http://www.sciencedaily.com/releases/2004/07/040728085123.htm
wink, wink....http://www.nanotech-now.com/news.cgi?story_id=07352
I'd like to see two things, an animal quantom dot panzem ncd experiment to see if the nano crystals are soaking the vessels and tumors, and a Abraxane-Panzem ncd combo phase one trial.
nottadoc....I think nanoparticles accumulate near leaky vessels, like the ones that nourish tumors, I wonder if they migrate to the leaky vessels in the back of the eye too.....http://www.nanocarrier.co.jp/d2_e.html
panzemNCD and abraxane?..eom
Abraxane was approved by the FDA yesterday.... "It appears that Abraxane allows for more cancer-fighting drug to be given to a patient,more of that drug to actually reach the tumor site in the body, and more of that drug to get inside of the tumor to fight cancer cells".....http://www.news-medical.net/?id=2473
I think ENMD has much more to go on the upside, much like OXGN ramp in 2003, just need a couple of PR's...http://www.thestreet.com/pf/stocks/biotech/10092336.html
blast from the past....#msg-2957260
AI success, bold statements.....http://www.dw-world.de/dw/briefs/0,1574,1449282.00.html
nottadoc...RE:early 2005, I'm glad we don't have to wait til spring, cool, we're on schedule.
check out Novartis news today......I'm thinking 2005 is going to be the year for angiogenesis inhibitors....a dot-com type bonanza
breast at Indiana, prostate at Wisconson?
obesity experiments...http://news.bbc.co.uk/2/hi/health/3699741.stm